Mutual cooperation based on the clinical research has been established among the CMG, the Laboratory of Experimental Haematology and Immunotherapy (LEHABI) at DCH FH Brno and the Veterinary Research Institute Brno. After two years of intensive investigation, the research resulted in developing the first Czech anti-cancer vaccination for patients with multiple myeloma that has been already applied to 12 patients. The investigation was supported by research target: Application of monoclonal immunoglobulin in vaccine development for patients with multiple myeloma (ID1/2002). Phase II clinical study (MZ 00065269705, Principal investigators: Prof. Roman Hájek, M.D./Ph.D. and T. Bűchler, M.D./ Ph.D.
Buchler T, Hajek R.: Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations.
Med Oncol. 2002;19(4):213-8. Review.
Buchler T, Michalek J, Kovarova L, Musilova R, Hajek R.: Dendritic cell-based immunotherapy for the treatment of hematological mclassancies.
Haematology. 2003 Apr;8(2):97-104. Review.